Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Research analysts at William Blair cut their Q4 2025 earnings estimates for Fortrea in a research report issued to clients ...

Equities researchers at William Blair decreased their Q1 2025 earnings estimates for Fortrea in a report released on Monday, ...

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.

For the three months and full-year ended December 31, 2024, from continuing operations:Revenues of $697.0 million for the fourth quarter, ...

Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...

Fortrea Holdings Inc. ( ($FTRE) ) has released its Q4 earnings. Here is a breakdown of the information Fortrea Holdings Inc. presented to its ...

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson ...